Investors seeking early visibility into emerging life sciences companies will have a direct line to management teams on September 17, 2026, when the Life Sciences Virtual Investor Forum convenes online. Hosted by Virtual Investor Conferences, an OTC Markets Group Inc. property, and marketed by B2i Digital, Inc., the event features seven companies presenting 30-minute live sessions with audience Q&A and on-demand replays. The forum matters because it compresses a broad cross-section of biotech innovation—from photothermal cancer therapy to cannabinoid-based formulations and a new class of antibiotics—into a single day, giving investors a rare chance to hear from executives in real time and ask impromptu questions that often reveal more than filings do.
According to David Shapiro, Chief Executive Officer of B2i Digital, Inc., "Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind." That sentiment underscores the forum's value: live interaction can surface details on strategy, timelines, and risk that static documents may obscure.
The presenting lineup spans several high-stakes areas. Sona Nanotech Inc. is developing a photothermal cancer therapy built on gold nanorods. Raphael Pharmaceutical focuses on cannabinoid-based formulations in development for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease. Amplia Therapeutics Ltd. brings a pipeline of Focal Adhesion Kinase inhibitors targeting cancer and fibrosis. Adaptin Bio, Inc. works on precision drug delivery technologies aimed at target tissues, including behind the blood-brain barrier. Acurx Pharmaceuticals, Inc. is advancing a new class of antibiotics for infections caused by bacteria listed as priority pathogens. CytoDyn Inc. is studying a humanized monoclonal antibody in solid-tumor oncology. 4DMedical Ltd. offers FDA-cleared four-dimensional respiratory imaging.
The forum's implications extend beyond any single company. By grouping oncology, fibrosis, drug delivery, antibiotics, cannabinoid therapeutics, and respiratory imaging into one event, it highlights how converging scientific platforms are reshaping treatment paradigms. For investors, the breadth offers a way to compare business models and scientific approaches across sectors that often trade on binary clinical milestones. The live format also levels the information playing field, letting retail and institutional investors alike hear directly from executives rather than relying solely on press releases or third-party summaries.
Event details and presenting company profiles are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum. Registration is open at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC. Replays will be posted on the B2i Digital and OTC Markets YouTube channels. Virtual Investor Conferences regularly features public companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and the OTC Markets. More information about B2i Digital's featured conferences is available at https://b2idigital.com.
